Cure My Disease

Don't miss your cure!

 Log in / Sign up

Contrast dye Double-Dose: new study tracks kidney fallout in ICU patients

NCT ID NCT07713524

Knowledge-focused Sponsor: Cairo University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This study follows 112 critically ill patients with pre-existing kidney disease who receive one or two doses of contrast dye for imaging. Researchers track kidney function, including acute injury and long-term decline, over six months. The goal is to understand how repeated contrast exposure impacts kidney outcomes in this vulnerable group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
iodinated contrast dye
What this could lead to
If it succeeds, this could help doctors better weigh the risks of using contrast dye in patients with weak kidneys, potentially preventing further kidney damage.
What could go wrong
This is an observational study, not a treatment trial, so it cannot prove cause and effect. Results may not apply to all ICU patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

112 people

The number who actually took part.

Started

Mar 2024

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with pre-existing renal impairment defined by KDIGO criteria who subjected to contrast exposure once or more

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older with baseline eGFR \<90 mL/min/1.73 m² who underwent at least one intravascular iodinated contrast study Exclusion Criteria: * Kidney transplant within the preceding 6 months * Ongoing renal replacement therapy * Hemodynamic shock * Severe sepsis * Recent nephrotoxic drug exposure * Incomplete laboratory data * Prior contrast allergy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease kidney disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney diseases

Contacts and locations

Locations

  • Faculty of medicine

    Cairo, KasrAlainy, 11562, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.